Ankit Kumar

Ankit Kumar

Active Director Director DIN 09067013
DIN 09067013 First appointment Feb 2021 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2021
Shareholding value •••• Premium profile

About Ankit Kumar

Data last updated:

Ankit Kumar is a Director at Sarcoma Remedies Private Limited (since 2021). The company operates in Pharma. Sarcoma Remedies Private Limited reported revenue of ₹3.65 Cr (FY 2025).

DIN 09067013
Primary Designation Director
Industry Pharma
First Appointment 11 Feb 2021
Oldest Company Age 11 yrs
Largest company Sarcoma Remedies Private Limited · ₹3.65 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sarcoma Remedies Private Limited U24239CH2015PTC035704
Director11 Feb 20212015₹3.65 Cr (FY 2025)Active

Board colleagues of Ankit Kumar

Directorship timeline

Open interactive timeline →
Sarcoma Remedies Private Limited
Premium access

Shareholding and investment profile for Ankit Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ankit Kumar

Ankit Kumar currently holds 1 directorship: Sarcoma Remedies Private Limited (Director, since 11 Feb 2021, revenue ₹3.65 Cr (FY 2025)).

Ankit Kumar was first appointed on 11 Feb 2021 as Director at Sarcoma Remedies Private Limited.

The current boards of Ankit Kumar's companies include Narendra Kumar (Sarcoma Remedies Private Limited), Swarn Singh (Sarcoma Remedies Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available